Pegylated-Interferon .Alfa. 2B (Peg-Ifn)
Hepatitis C Virus Infection
Merck Sharp & Dohme LLCprotein_peptidePhase 4 / ApprovedDormant
BB
70/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 55/ 100
- Competitive Position
- 95/ 100
Competitive context
12 Active assets in the Hepatitis C Virus Infection cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Veruprevir AbbVie | Phase 4 | A |
Daclatasvir MTI University | Phase 4 | A |
Pibrentasvir AbbVie | Phase 3 | A |
Velpatasvir Peking University People's Hospital | Phase 4 | A |
Glecaprevir AbbVie | Phase 3 | A |
View all 50 →
Same molecule, other indications
Pegylated-Interferon .Alfa. 2B (Peg-Ifn) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →